MedTrace Logo

Serratus Plane Block After Minimally Invasive Mitral Valve Repair

NCT05648266 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-10-02

No results posted yet for this study

Summary

Patients undergoing minimally invasive mitral valve reconstruction via small thoracotomy are randomized into two groups.

The intervention group receives serratus anterior plane block after minimally invasive mitral-valve reconstruction, following 48h infusion with ropivacaine 2% continually.

The control group receives a placebo pump without infusion. Primary endpoints are perceived pain using a numeric pain rating scale and opioid consumption during the hospital stay.

Conditions

  • Minimal Invasive Cardiac Surgery
  • Minimal Invasive Cardiac Surgery Mitral Valve Surgery
  • Serratus Anterior Plane Block

Interventions

DRUG

Continous SAPB (Ropivacain)

postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h

OTHER

institutional standard of care pain medication protocol

institutional standard of care pain medication protocol

Sponsors & Collaborators

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-07-01
Completion
2024-07-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05648266 on ClinicalTrials.gov